| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0360-3016(01)02819-X |
| P698 | PubMed publication ID | 12007942 |
| P2093 | author name string | Chang E | |
| Yung WK | |||
| Levin VA | |||
| Leeds N | |||
| Meyers CA | |||
| Bruner J | |||
| Hess KR | |||
| Gleason MJ | |||
| Maor MH | |||
| Kyritsis A | |||
| Ictech SA | |||
| P2860 | cites work | Cisplatin in the treatment of recurrent childhood primary brain tumors | Q48166638 |
| Radiation therapy for neoplasms of the brain | Q48254666 | ||
| Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors | Q48267884 | ||
| Radiosurgery as part of the initial management of patients with malignant gliomas | Q48442562 | ||
| Advantage of Post-Radiotherapy Chemotherapy with CCNU, Procarbazine, and Vincristine (mPCV) Over Chemotherapy with VM-26 and CCNU for Malignant Gliomas | Q48503073 | ||
| Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques | Q48784871 | ||
| Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. | Q51074035 | ||
| Cerebral radionecrosis: Incidence and risk in relation to dose, time, fractionation and volume | Q55490446 | ||
| Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme | Q72054576 | ||
| Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion | Q72743025 | ||
| White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02) | Q72789418 | ||
| The influence of time sequence of cisplatin administration and continuous low dose rate irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma | Q93648653 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Intravenous carboplatin for recurrent malignant glioma: a phase II study | Q33379721 | ||
| Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma | Q33493587 | ||
| Current treatment of oligodendrogliomas | Q33591771 | ||
| A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. | Q33804983 | ||
| Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study | Q34239497 | ||
| Evaluation of bromodeoxyuridine in glioblastoma multiforme: A A Northern California cancer center phase II study | Q36411896 | ||
| Carboplatin as a potentiator of radiation therapy | Q39838939 | ||
| Oligodendroglioma: an analysis of prognostic factors and treatment results | Q40768855 | ||
| Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors | Q46041152 | ||
| Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas | Q46093579 | ||
| External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2 gliomas: NCOG study 6H-82-2 | Q46293640 | ||
| Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report | Q46364938 | ||
| Sample size considerations for studies comparing survival curves using historical controls | Q47187328 | ||
| Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma | Q48106629 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| carboplatin | Q415588 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 58-66 | |
| P577 | publication date | 2002-05-01 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas | |
| P478 | volume | 53 |
| Q53299361 | A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma. |
| Q36089590 | CNS Anticancer Drug Discovery and Development Conference White Paper. |
| Q81086312 | Central nervous system tumors |
| Q33697950 | Chemotherapy-related changes in cognitive functioning |
| Q37997653 | Chemotherapy-related cognitive dysfunction |
| Q36926781 | Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology |
| Q37744732 | Effects of irradiation on tumor cell survival, invasion and angiogenesis |
| Q45062497 | Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. |
| Q38827937 | Extent of Resection in Glioma-A Review of the Cutting Edge. |
| Q48177906 | External beam and conformal radiotherapy in the management of gliomas |
| Q37170201 | Glioma extent of resection and its impact on patient outcome |
| Q44306496 | Glioma treatment, radionecrosis, and growth factors. In regard to Levin et al., IJROBP 2002;53:58-66. |
| Q49795787 | Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment |
| Q48770142 | Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. |
| Q90972144 | Management of Glioblastoma, Present and Future |
| Q31095748 | Maximizing safe resection of low- and high-grade glioma |
| Q36681524 | Net clinical benefit: functional endpoints in brain tumor clinical trials |
| Q30426728 | Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab |
| Q38055317 | Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities |
| Q37608907 | New advances that enable identification of glioblastoma recurrence. |
| Q79222530 | Oligodendroglioma |
| Q37533640 | Operative techniques for gliomas and the value of extent of resection |
| Q42243011 | Penetration of intra-arterially administered vincristine in experimental brain tumor |
| Q37119118 | Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood |
| Q38892293 | Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors |
| Q33315042 | Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas |
| Q46723190 | Role of surgical resection in low- and high-grade gliomas |
| Q34471159 | Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma |
| Q38204718 | The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline |
| Q38054083 | The value of glioma extent of resection in the modern neurosurgical era. |
| Q36107175 | Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. |
Search more.